Pfizer considers antiviral options as Paxlovid use skyrockets amid worries of resistance
When Pfizer’s Covid-19 antiviral Paxlovid first hit the shelves last December, it was widely seen as the best option to keep those at high risk …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
